2-chloro-4-[(Z)-2-ethoxyvinyl]-5-fluoropyrimidine | 878805-32-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-chloro-4-[(Z)-2-ethoxyvinyl]-5-fluoropyrimidine
• 英文别名: 2-chloro-4-[(Z)-2-ethoxyethenyl]-5-fluoropyrimidine
• CAS: 878805-32-4
• 化学式: C₈H₈ClFN₂O
• 分子量: 202.616
• InChiKey: UADDTIOQKJMMJO-ARJAWSKDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-chloro-4-[(Z)-2-ethoxyvinyl]-5-fluoropyrimidine 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  WO2008/81910

  摘要：

  公开号：
• 作为产物：
  描述：

  三丁基(2-乙氧基乙烯基)锡 、 2,4-二氯-5-氟嘧啶 在 bis-triphenylphosphine-palladium(II) chloride potassium fluoride 作用下， 以 乙腈 、 水 为溶剂， 反应 3.0h， 生成 2-chloro-4-[(Z)-2-ethoxyvinyl]-5-fluoropyrimidine
  参考文献：
  名称：

  WO2008/81910

  摘要：

  公开号：

文献信息

• Novel Substituted Imidazole Derivative
  申请人：Kawamura Mikako

  公开号：US20080070894A1

  公开（公告）日：2008-03-20

  The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein: X 1 , X 2 , X 3 , and X 4 , which may be identical or different, are each C or N, provided that none to two of X 1 , X 2 , X 3 , and X 4 is/are N; Y is CH or N; R 1 , R 1 ′, R 2 , R 2 ′, R 3 , R 3 ′, R 4 , and R 4 ′, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R 5 is a hydrogen atom or a methyl group; R 6 and R 7 , which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R 8 and R 8 ′, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R 9 is an aryl group or a heteroaryl group which may be substituted; and n is an integer from 1 to 3, and a PLK1 inhibitor or an anticancer agent containing the same.

  本发明涉及一种由式[I]表示的化合物或其药学上可接受的盐或酯：其中，X1、X2、X3和X4可以相同也可以不同，分别为C或N，但是X1、X2、X3和X4中至少有一个或最多两个是N；Y为CH或N；R1、R1'、R2、R2'、R3、R3'、R4和R4'可以相同也可以不同，分别为氢原子、低碳基或类似物；R5为氢原子或甲基基团；R6和R7可以相同也可以不同，分别为氢原子、低碳基或类似物；R8和R8'可以相同也可以不同，分别为氢原子、低碳基或类似物；R9为取代的芳基或杂环基；n为1到3的整数。本发明还涉及一种PLK1抑制剂或含有该化合物的抗癌剂。
• Novel aminopyrimidine derivatives as PLK1 inhibitors
  申请人：Hashihayata Takashi

  公开号：US20080305081A1

  公开（公告）日：2008-12-11

  The present invention relates to a compound represented by Formula [I]: or a pharmaceutically acceptable salt or ester thereof, wherein R 1 and R 2 , which may be the same or different, are each a hydrogen atom, a lower alkyl group, a cycloalkyl group, or the like; R 3 and R 4 , which may be the same or different, are each a hydrogen atom, a lower alkyl group, NR a R b , a phenyl group, a lower alkyl group substituted with a phenyl group, a 4- to 7-membered aliphatic heterocyclic group, a lower alkyl group substituted with a 4- to 7-membered aliphatic heterocyclic group, a 5- or 6-membered aromatic heterocyclic group, a lower alkyl group substituted with a 5- or 6-membered aromatic heterocyclic group, or the like; and R 5 is a hydrogen atom, a cyano group, a halogen atom, or a lower alkyl group.

  本发明涉及由公式[I]表示的化合物，或其药学上可接受的盐或酯，其中R1和R2（可以相同也可以不同）分别是氢原子、低碳基、环烷基或类似物；R3和R4（可以相同也可以不同）分别是氢原子、低碳基、NRaRb、苯基、带苯基的低碳基、4-至7-成员的脂环杂环基、带4-至7-成员的脂环杂环基的低碳基、5-或6-成员的芳香杂环基、带5-或6-成员的芳香杂环基的低碳基或类似物；R5是氢原子、氰基、卤素原子或低碳基。
• Aminopyrimidine derivatives as PLK1 inhibitors
  申请人：Banyu Pharmaceutical Co. Ltd

  公开号：US07977336B2

  公开（公告）日：2011-07-12

  The present invention relates to a compound represented by Formula [I]: or a pharmaceutically acceptable salt or ester thereof, wherein R1 and R2, which may be the same or different, are each a hydrogen atom, a lower alkyl group, a cycloalkyl group, or the like; R3 and R4, which may be the same or different, are each a hydrogen atom, a lower alkyl group, NRaRb, a phenyl group, a lower alkyl group substituted with a phenyl group, a 4-to 7-membered aliphatic heterocyclic group, a lower alkyl group substituted with a 4- to 7-membered aliphatic heterocyclic group, a 5-or 6-membered aromatic heterocyclic group, a lower alkyl group substituted with a 5-or 6-membered aromatic heterocyclic group, or the like; and R5 is a hydrogen atom, a cyano group, a halogen atom, or a lower alkyl group.

  本发明涉及一种由式[I]表示的化合物，或其药学上可接受的盐或酯，其中R1和R2，可以相同也可以不同，分别是氢原子，低碳基，环烷基或类似物；R3和R4，可以相同也可以不同，分别是氢原子，低碳基，NRaRb，苯基，带有苯基的低碳基，4-至7-成员脂环杂环基，带有4-至7-成员脂环杂环基的低碳基，5-或6-成员芳香杂环基，带有5-或6-成员芳香杂环基的低碳基或类似物；而R5是氢原子，氰基，卤素原子或低碳基。
• NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1790650A1

  公开（公告）日：2007-05-30

  The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein: X1, X2, X3, and X4, which may be identical or different, are each C or N, provided that none to two of X1, X2, X3, and X4 is/are N; Y is CH or N; R1, R1', R2, R2', R3, R3', R4, and R4', which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R5 is a hydrogen atom or a methyl group; R6 and R7, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R8 and R8', which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R9 is an aryl group or a heteroaryl group which may be substituted; and n is an integer from 1 to 3, and a PLK1 inhibitor or an anticancer agent containing the same.

  本发明涉及一种由式[I]代表的化合物或其药学上可接受的盐或酯： 其中 X1、X2、X3和X4（可以相同或不同）各自是C或N，条件是X1、X2、X3和X4中没有一个至两个是/是N； Y 是 CH 或 N； R1、R1'、R2、R2'、R3、R3'、R4 和 R4'（可以相同或不同）各自是氢原子、低级烷基或类似物； R5 是氢原子或甲基； R6 和 R7 可以相同或不同，各自为氢原子、低级烷基或类似物； R8 和 R8'可以相同或不同，各自为氢原子、低级烷基或类似物； R9 是芳基或杂芳基，可被取代；以及 n 是 1 至 3 的整数、 以及 PLK1 抑制剂或含有相同成分的抗癌剂。
• NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP2116543A1

  公开（公告）日：2009-11-11

  The present invention relates to a compound represented by Formula [I]: or a pharmaceutically acceptable salt or ester thereof, wherein R1 and R2, which may be the same or different, are each a hydrogen atom, a lower alkyl group, a cycloalkyl group, or the like; R3 and R4, which may be the same or different, are each a hydrogen atom, a lower alkyl group, NRaRb, a phenyl group, a lower alkyl group substituted with a phenyl group, a 4- to 7-membered aliphatic heterocyclic group, a lower alkyl group substituted with a 4- to 7-membered aliphatic heterocyclic group, a 5- or 6-membered aromatic heterocyclic group, a lower alkyl group substituted with a 5- or 6-membered aromatic heterocyclic group, or the like; and R5 is a hydrogen atom, a cyano group, a halogen atom, or a lower alkyl group.

  本发明涉及一种由式 [I] 表示的化合物： 或其药学上可接受的盐或酯，其中R1和R2可以相同或不同，各自为氢原子、低级烷基、环烷基或类似物；R3 和 R4（可以相同或不同）各自是氢原子、低级烷基、NRaRb、苯基、被苯基取代的低级烷基、4-7 元脂肪杂环基、被 4-7 元脂肪杂环基取代的低级烷基、5-或 6 元芳香杂环基、被 5-6 元芳香杂环基取代的低级烷基或类似基团；R5 是氢原子、氰基、卤素原子或低级烷基。